Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | JAK1 V658F |
Gene Variant Detail | |
Relevant Treatment Approaches | JAK Inhibitor (Pan) JAK Inhibitor (Pan) - ATP competitive JAK1 Inhibitor JAK1 Inhibitor - ATP competitive |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
JAK1 V658F | cancer | sensitive | JAK1 Inhibitor - ATP competitive | Ruxolitinib | Preclinical | Actionable | In a preclinical study, transformed cells expressing JAK1 V658F were sensitive to ATP-competitive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331). | 21393331 |
JAK1 V658F | hematologic cancer | sensitive | SHP099 | Preclinical | Actionable | In a preclinical study, SHP099 inhibited proliferation of a hematopoietic cancer cell line harboring JAK1 V658F in culture (PMID: 27362227). | 27362227 | |
JAK1 V658F | hematologic cancer | sensitive | JAK1 Inhibitor - ATP competitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) inhibited Stat5 phosphorylation and viability in a cell line expressing JAK1 V658F in culture (PMID: 36786170). | 36786170 |
JAK1 V658F | hematologic cancer | sensitive | JAK1 Inhibitor - ATP competitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) inhibited proliferation of a cell line expressing JAK1 V658F in culture (PMID: 39091915). | 39091915 |
JAK1 V658F | hematologic cancer | sensitive | LGH447 | Preclinical - Cell culture | Actionable | In a preclinical study, LGH447 inhibited viability and proliferation of transformed cells expressing JAK1 V658F in culture (PMID: 39033228). | 39033228 |